Replies to post #10178 on RespireRx Pharmaceuticals Inc (fka RSPI)

[vsualyzprofits]

<<…I, however, would like the co. to provide more of the details.>>

If my interpretation of your post is correct, the complete details of the financing are available on the web if you take the time to look for them. Granted, it is tedious reading, however all the gory details, money paid out, money coming in, etc., are there for all to read. Remember, this is a public company and it is mandatory that their financial dealings be made public. I have looked at the documents and didn’t like what I saw either, however I still believe they made the best deal they could make “at the time,” pending the looming dour economic market.

Regards, Judy

P.S. Iggs - please check your mailbox.

[neuroinv]

1) Ms. Messinger does not execute the CFO duties that most of her peers do--she plays no part in fundraising that I can discern. I posted a couple weeks ago that Cortex should consider hiring a real CFO--who can lead the fundraising efforts. Messinger appears to run company finances--but that is different from developing and utilizing financing sources.
2) All negotiations are done under a CDA--confidentiality agreement. Cortex cannot tell other people; Merck offered us $41 million, beat that. But I expect there will be more than one company that will say--call us before you accept any other bid. They could call Lilly, whose bid is at $38 million upfront, and say--we have an offer we are going to accept--unless you can come up $4 million from your previous bid. That does not violate the CDA.
3) <<If Stoll were to decide to step down on Monday and a new qualified CEO was named, I would guess that this stock would be back over $2.00.>> Really? I guess we'll never know, but I think the stock would be at 1.25.

NeuroInvestment